Yarrow Bioscience, Inc. Common Stock
YARW
53 hedge funds and large institutions have $139M invested in Yarrow Bioscience, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
103% more capital invested
Capital invested by funds: $68.4M → $139M (+$70.6M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
18% more funds holding
Funds holding: 45 → 53 (+8)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$6.22M |
| 2 |
O
OrbiMed
New York
|
+$4.22M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 5 |
DM
Deerfield Management
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.23M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$1.06M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$984K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$696K |
| 5 |
JP Morgan Chase
New York
|
-$576K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $19K | – | – | – |
|
52
BNP Paribas Financial Markets
Paris,
France
| $16.5K | +$24K | +1 | New |
|
53
UBS Group
Zurich,
Switzerland
| $15K | -$24K | -1 | -50% |
|
54
Legal & General Group
London,
United Kingdom
| $9K | – | – | – |
|
|
MAM
55
Meeder Asset Management
Dublin,
Ohio
| $7K | – | – | – |
|
|
AIP
56
Ameritas Investment Partners
Lincoln,
Nebraska
| $4K | – | – | – |
|
57
Federated Hermes
Pittsburgh,
Pennsylvania
| $4K | – | – | – |
|
58
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | – | – | – |
|
|
PCP
59
Proficio Capital Partners
Newton,
Massachusetts
| $1K | – | – | – |
|
|
NHAS
60
Novo Holdings A/S
Hellerup,
Denmark
| – | -$5.23M | -353 | Closed |
|
|
MWNA
61
Marshall Wace North America
New York
| – | -$80K | -5 | Closed |
|
62
Citadel Advisors
Miami,
Florida
| – | -$57K | -4 | Closed |
|
63
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
64
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | – | – |
|
65
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$5K | – | – |
|
66
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | – | – |
|
YARW Hedge Fund Activity: Q1 2019 in Review
53 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q1 2019, worth a combined $139M — up 103% from $68.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new YARW positions and 3 closed out — a net gain of 8 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was First Manhattan, adding an estimated $6.22M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.23M sold.
- 53 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q1 2019, up from 45 in Q4 2018.
- Funds reported $139M of Yarrow Bioscience, Inc. Common Stock stock for Q1 2019, up 103% quarter-over-quarter.
- 11 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q1 2019 and 3 closed out, a net change of +8 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q1 2019 was First Manhattan, an estimated $6.22M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q1 2019 was Novo Holdings A/S, an estimated $5.23M sold.
Based on aggregated 13F filings for Q1 2019.